PRECISE: Pancreatic Cancer and Exercise
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04305067|
Recruitment Status : Not yet recruiting
First Posted : March 12, 2020
Last Update Posted : March 12, 2020
|Condition or disease||Intervention/treatment||Phase|
|Pancreas Adenocarcinoma||Other: Exercise||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||PRECISE: PancREatic Cancer and Individualised Supervised Exercise: a Feasibility Study|
|Estimated Study Start Date :||March 1, 2020|
|Estimated Primary Completion Date :||July 31, 2021|
|Estimated Study Completion Date :||July 31, 2021|
Experimental: Supervised aerobic and resistance exercise
16 weeks of supervised, moderate intensity, aerobic and resistance exercise. Aerobic exercise will be completed supervised, 2 days per week, commencing with a single 10 minute bout and progressing to 30 minutes of continuous aerobic exercise. Resistance exercises will involve whole body activities and commence with 1 set of each exercise (6-12 repetitions) and progress to 3 sets. The resistance exercises will gradually progress in difficulty throughout the program and will utilise daily undulating periodisation
Exercise programs will be individually tailored to the capabilities of each participant and gradually progressed accordingly. Each patient will be asked to complete one home-based aerobic exercise sessions each week. At baseline, 16 weeks and 3 month followup patients will complete a physical fitness assessment (30 second sit to stand and six minute walking tests) and a range of quality of life questionnaires. Upon completion of the 16 week exercise intervention, patients will be invited to partake in semi-structured interviews to determine the effectiveness of the program and their experience throughout.
- Feasibility - recruitment: number of participants that agree to participate or are excluded [ Time Frame: At baseline ]The number of participants that agree to participate or are excluded
- Feasibility - attrition: number of participants that withdraw from the study [ Time Frame: At conclusion of the 16 week exercise intervention ]The number of participants that withdraw from the study
- Feasibility - adherence to the exercise intervention: percentage of participants adhering to the exercise intervention [ Time Frame: At conclusion of the 16 week exercise intervention ]Determine the percentage of participants adhering to the exercise intervention
- Feasibility - participant experience: semi-structured interviews [ Time Frame: At conclusion of the 16 week exercise intervention ]Determined by qualitative evaluation, using semi-structured interviews to assess experiences, accessibility and acceptability of the exercise intervention
- Anthropometric assessment [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]Height will be measured in cm and body weight in k, which will be combined to report BMI in kg/m (squared).
- Hip and waist circumference analysis [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]Hip and waist circumference will be measured in cm.
- Functional muscle endurance assessment [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]The amount of repetitions achieved during a 30 second sit-to-stand test will be recorded.
- Physical fitness assessment [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]Distance covered in meters during a six minute walk test will be recorded.
- Perceived physical activity levels [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]Patients will complete an International Physical Activity Questionnaire (IPAQ-SF). This questionnaire will comprise 4 generic items to obtain comparable health-related physical activity. Patients will detail the number of days, hours and minutes that they undertake (1) vigorous exercise (2) moderate exercise (3) walking exercise and (4) sitting. Total physical activity will be generated and monitored for improvement or decline. Higher reported scores indicate higher levels of self-reported physical activity.
- Cancer-related fatigue by questionnaire [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]Fatigue will be measured by the Functional Assessment of Cancer Therapy - Fatigue (FACIT-Fatigue) questionnaire. Patients will score several fatigue items over the past 7 days on a scale (0 = not at all; 4 = very much), generating a total (0 - 52) with higher scores linked to greater quality of life.
- Patient rated pain by questionnaire [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]Pain will be measured using the Brief Pain Inventory (BPI). Pain is scored on a scale 0 - 10, with higher scores indicating higher pain levels.
- Health related quality of life by questionnaire [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]Quality of life will be measured by the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) questionnaire. This questionnaire is scored on a scale of 0 - 4, with 0 indicating not at all, and 4 indicating very much. Higher scores indicate poorer quality of life.
- Health related quality of life by questionnaire [ Time Frame: At baseline, 16 weeks, 3 month follow-up ]Quality of life will be measured by the EuroQOL Five Dimension Questionnaire (EQ5D). Patients will select a level of difficulty (I have no - I have extreme) on that particular days health for mobility, self-care, usual activities, pain / discomfort and anxiety / depression. Patients will then rate 'how good' or 'how bad' their health is on that day using a 100 point scale (0 = worst health you can imagine; 100 = best health you can imagine).
- Health economics [ Time Frame: At 16 weeks ]Health resource use will be evaluated by a Health Economics Questionnaire
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04305067
|Contact: Gillian Prue, PhDemail@example.com|
|Contact: Dominic O'Connor, PhDfirstname.lastname@example.org|
|Principal Investigator:||Richard Turkington, MD||Queens University|